Is Type 2 Diabetes Mellitus A Risk Factor For Gallbladder, Biliary And Pancreatic Cancer?
Posted on: Thursday, 19 November 2009, 14:51 CST
There are minimal data assessing the relationship between diabetes with gallbladder, biliary and pancreatic cancer. Recent small studies have suggested an elevated risk of pancreatic cancer only in patients with diabetes mellitus (DM).
A research article published on November 14, 2009 in the World Journal of Gastroenterology addresses this question. The research team, lead by Dr. Jamal at the Veterans Affairs Medical Center, Long Beach, California, performed a retrospective search of type 2 DM patients matched to non-diabetic controls, discharged from Department of Veterans Affairs hospitals from 1990 to 2000, for the presence of gallbladder, biliary and pancreatic cancer. The database search identified 1 172 496 cases and control subjects for analysis. There was no difference in mean age between the case and control groups. Among patients with type 2 DM, the incidence of pancreatic cancer was increased threefold compared to controls, and gallbladder and extrahepatic biliary cancers were increased by twofold compared to controls.
This is the first study to provide a comprehensive assessment of the risk for gallbladder, biliary and pancreatic cancers in a large cohort of patients with type 2 DM. This study suggests future avenues for investigation to determine preventive measures and screening implementation strategies, to limit the impact of these tumors in the veteran as well as general type 2 DM population in the United States.
---
On the Net:
Related Articles
- Oncology Social Workers Report 'Uncertain' and 'Unknown' Cancers Significantly Increase Patient Distress
- Pro-Pharmaceuticals Announces ''Compassionate Use'' IND for DAVANAT(R) to Treat Biliary Cancer Patient
- Pro-Pharmaceuticals Announces Tampa General Hospital Dosing Patients With DAVANAT(R)/5-FU in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
- Pro-Pharmaceuticals Starts Dosing in Biliary Cancer Study
- Pro-Pharmaceuticals Announces Dosing of Patients With DAVANAT(R) in Phase II, First Line, Advanced Biliary Cancer Clinical Trial
- Pro-Pharmaceuticals Signs Agreement With CESAR to Expand Recruitment of Patients for the Phase II Biliary Cancer Trial
- ImClone Systems Announces Complete Enrollment of Several Studies Examining Potential Survival Benefit Of ERBITUX(R) In Three Major Cancer Types
- Glycemic and Lipid Control in Hospitalized Type 2 Diabetic Patients: Evaluation of 2 Enteral Nutrition Formulas (Low Carbohydrate-High Monounsaturated Fat Vs High Carbohydrate)
- Orlistat Augments Postprandial Increases in Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Damci Et Al./ Orlistat Augments Postprandial Increases In Glucagon-Like Peptide-1 in Obese Type 2 Diabetic Patients: Response to Horowitz Et
- Impact of Changes in HbA^Sub 1c^, Lipids and Blood Pressure on Long- Term Outcomes in Type 2 Diabetes Patients: An Analysis Using the CORE Diabetes Model
 |
 |
User Comments (0)
RSS Feeds